HPV vaccine may prevent multiple cancer types

Getting your Trinity Audio player ready...

Washington: The human papilloma virus (HPV) vaccine, Cervarix, not

only has the potential to prevent cervical cancer but also other

HPV-caused common cancer types, shows a multinational clinical trial,

involving nearly 20,000 young women.

That effectiveness endured for the study's entire follow-up, of up to

four years, the researchers noted.

"The study confirms that targeting young adolescent girls before

sexual debut for prophylactic HPV vaccination has a substantial impact

on the incidence of high grade cervical abnormalities," said

corresponding author Dan Apter, director, The Sexual Health Clinic,

Family Federation of Finland, Helsinki.

The vaccine was extremely effective in young women who had never been

infected with HPV.

It protected nearly all from HPV-16 and 18, and protected 50-100

percent against different grades of precancerous transformation of

cervical cells caused by other strains of HPV.

The women were followed for up to four years post-vaccination.

The vaccine was distinctly more effective among those aged 15-17 than

those aged 18-25, underscoring the value of vaccinating young

adolescents, Apter added.

The lower efficacy in the oldest age group may result from a larger

proportion of women in that age group having had persistent infections

at the time of vaccination, he said.

The study is the final report from the Papilloma Trial Against Cancer

in Young Adults (PATRICIA), a multinational clinical trial,

encompassing 14 countries in Europe, the Asia-Pacific region, North

America, and Latin America, and it confirms previous reports in this


The study appeared in the journal Clinical and Vaccine Immunology.

Credit: ANI

Kofi Oppong Kyekyeku

I am a Ghanaian Broadcast Journalist/Writer who has an interest in General News, Sports, Entertainment, Health, Lifestyle and many more.

Related Articles

Leave a Reply

Back to top button